Clinical Hematology International最新文献

{"title":"Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series.","authors":"Shamis Khan, Sara Taveras Alam, Rosa Torres Ramos, John Etumbani Mbue, Effrosyni Apostolidou, Gustavo A Rivero, Sarvari Venkata Yellapragada","doi":"10.1007/s44228-022-00016-4","DOIUrl":"https://doi.org/10.1007/s44228-022-00016-4","url":null,"abstract":"","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 4","pages":"148-151"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10484550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Standing on the Shoulders of the Giants': Dr Rainer Storb.","authors":"Mohamad Mohty, Rainer Storb","doi":"10.1007/s44228-022-00018-2","DOIUrl":"https://doi.org/10.1007/s44228-022-00018-2","url":null,"abstract":"","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 4","pages":"121-126"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities.","authors":"Rose Ellard,&nbsp;Michelle Kenyon,&nbsp;Daphna Hutt,&nbsp;Erik Aerts,&nbsp;Maaike de Ruijter,&nbsp;Christian Chabannon,&nbsp;Mohamad Mohty,&nbsp;Silvia Montoto,&nbsp;Elisabeth Wallhult,&nbsp;John Murray","doi":"10.1007/s44228-022-00004-8","DOIUrl":"https://doi.org/10.1007/s44228-022-00004-8","url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CAR T) therapy is a new and rapidly developing field. Centers across the world are gaining more experience using these innovative anti-cancer treatments, transitioning from the 'bench' to the 'bedside', giving benefit to an increasing number of patients. For those with some refractory hematological malignancies, CAR-T may offer a treatment option that was not available a few years ago.CAR-T therapy is an immune effector cell and precision/personalized medicine treatment which is tailored to the individual patient and associated with a variety of unique adverse events and toxicities that necessitate specialist nursing/medical vigilance in an appropriate clinical setting. Subtle unrecognized signs and symptoms can result in rapid deterioration and, possibly, life threatening cardiorespiratory and/or neurological sequelae.These guidelines have been prepared for nurses working in cellular therapy in inpatient, outpatient and ambulatory settings. Many nurses will encounter cellular therapy recipients indirectly, during the referral process, following discharge, and when patients are repatriated back to local centers. The aim of these guidelines is to provide all nurses with a practice framework to enable recognition, monitoring and grading of CAR-T therapy-associated toxicities, and to support and nurse these highly complex patients with confidence.They have been developed under the auspices of several bodies of the European society for Blood and Marrow Transplantation (EBMT), by experienced health professionals, and will be a valuable resource to all practitioners working in cellular therapy.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 3","pages":"75-88"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9679707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.","authors":"Caroline Dartigeas,&nbsp;Borhane Slama,&nbsp;Margaret Doyle,&nbsp;Christoph Tapprich,&nbsp;Claire Albrecht,&nbsp;Sandrine Dupuis,&nbsp;Robert Wapenaar,&nbsp;Charlotte Schmidt-Hieber,&nbsp;Veronique Leblond","doi":"10.1007/s44228-022-00015-5","DOIUrl":"https://doi.org/10.1007/s44228-022-00015-5","url":null,"abstract":"<p><p>The FIRE study investigated the real-world effectiveness and safety of ibrutinib in prospectively observed patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France. Patients were mostly relapsed/refractory with high-risk features. First-line CLL/SLL patients had del17p and/or TP53 mutations. In this interim analysis, the median follow-up time for patients with CLL/SLL and MCL was 17.7 and 15.1 months, respectively. In the effectiveness populations for CLL/SLL (n = 200) and MCL (n = 59), the median progression-free survival was not estimable and 12.4 months, respectively; the 12-month overall survival rates were 88.5% and 65.8%, respectively. Treatment-emergent adverse events of interest for patients with CLL/SLL (n = 202) and MCL (n = 59) included: infections and infestations (53.5% and 32.2%), major bleeding (5.0% and 5.1%), and atrial fibrillation (5.9% and 8.5%); 135 (66.8%) and 20 (33.9%) patients were continuing treatment at the time of data cutoff. Future analyses will report on longer-term follow-up (Trial registration: ClinicalTrials.gov, NCT03425591. Registered 1 February 2018-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03425591 ).</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":" ","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40357717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.","authors":"Sayako Yuda,&nbsp;Shigeo Fuji,&nbsp;Bipin Savani,&nbsp;Katie S Gatwood","doi":"10.1007/s44228-022-00012-8","DOIUrl":"https://doi.org/10.1007/s44228-022-00012-8","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":" ","pages":"89-98"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4⁺ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.","authors":"Katrine Fladeland Iversen,&nbsp;Line Nederby,&nbsp;Thomas Lund,&nbsp;Torben Plesner","doi":"10.1007/s44228-022-00013-7","DOIUrl":"https://doi.org/10.1007/s44228-022-00013-7","url":null,"abstract":"<p><p>Multiple myeloma is an incurable disease characterized by unregulated growth of malignant plasma cells in the bone marrow (BM). Tumor-induced dysfunction of T-cells may be responsible for immune evasion and failure of immunotherapy. Therefore, a better understanding of the phenotype of T-cells at the tumor site is needed. We assessed the expression of immune regulatory receptors on T-cell subsets from peripheral blood (PB) and BM using multicolor flow cytometry. Paired PB and BM samples were collected from newly diagnosed, treatment-naïve myeloma patients (n = 19) and patients progressing during treatment with the CD38 monoclonal antibody daratumumab alone or in combination with other anti-myeloma drugs (n = 39). We observed that CD4⁺ T-cells from both PB and BM of patients relapsing on daratumumab have a higher expression of the costimulatory checkpoint receptor DNAM-1. The potential role of DNAM-1⁺CD4⁺ T-cells in the development of resistance to daratumumab needs further exploration. We also observed that the inhibitory checkpoint receptor TIGIT is more frequently expressed by BM CD8⁺ T-cells from myeloma patients than PD-1 and CTLA-4, which supports the hypothesis that TIGIT may play a central role in the immune escape of the malignant plasma cells.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":" ","pages":"107-116"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizational Challenges in the Pediatric Onco-hematology Units During the First and Second Wave of the COVID-19 Pandemic: A National Survey in Italy.","authors":"Matteo Amicucci,&nbsp;Valentina Biagioli,&nbsp;Elena Rostagno,&nbsp;Marta Canesi,&nbsp;Anna Bergadano,&nbsp;Debora Botta,&nbsp;Moreno Crotti Partel","doi":"10.1007/s44228-022-00010-w","DOIUrl":"https://doi.org/10.1007/s44228-022-00010-w","url":null,"abstract":"<p><p>This study aimed to describe and compare, at a national level, the measures implemented in the pediatric onco-hematology units and the number of infections among patients and healthcare staff during the first and second wave of the COVID-19 pandemic in Italy. A multicenter, descriptive, online survey was conducted between15th March and 15th April 2020 (T1) and between 1 and 31st January 2021 (T2). All the Italian Pediatric Oncology and Hematology Association (AIEOP) centers were invited to participate in the study. Data of the pre-pandemic, first, and second phase were compared. Thirty-six of the 48 AIEOP centers completed the survey (75%). Several organizational, screening, and swab measures were implemented by AIEOP centers to prevent the SARS-CoV-2 infection among patients and visitors. During the pandemic, there was a significant reduction in the number of onco-hematology inpatient beds (p < 0.001), including inpatient beds dedicated to hematopoietic stem cell transplantation (HSCT), and consultations in the outpatient clinics (p < 0.001). During the first wave, 37 pediatric patients with cancer tested positive for SARS-CoV-2 versus 174 patients during the second wave. The reduction in routine services was also greater in the second than in the first wave. All the AIEOP centers showed the capacity to adapt and promptly respond to both waves of the pandemic.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 3","pages":"99-106"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9221701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.","authors":"Samer Al Hadidi,&nbsp;Deepa Dongarwar,&nbsp;Hamisu Salihu,&nbsp;Carolina Schinke,&nbsp;Sharmilan Thanendrarajan,&nbsp;Maurizio Zangari,&nbsp;Frits van Rhee","doi":"10.1007/s44228-022-00014-6","DOIUrl":"https://doi.org/10.1007/s44228-022-00014-6","url":null,"abstract":"","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":" ","pages":"117-120"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas.","authors":"Ibrahim N Muhsen,&nbsp;Riad El Fakih,&nbsp;Mehdi Hamadani,&nbsp;Hillard M Lazarus,&nbsp;Mohamed A Kharfan-Dabaja,&nbsp;Mahmoud Aljurf","doi":"10.1007/s44228-022-00011-9","DOIUrl":"https://doi.org/10.1007/s44228-022-00011-9","url":null,"abstract":"<p><p>Primary cutaneous <i>γδ</i> T-cell lymphoma (PCGDTL) is a rare subtype of non-Hodgkin lymphoma (NHL) that arises from T-cells with <i>γδ</i> T-cell receptors. The exact incidence of PCGDTL is unknown, as it is usually lumped with other cutaneous lymphomas, which are also uncommon. It is one of the peripheral T-cell lymphoma (PTCL) subtypes which is known to have a dismal prognosis due to poor response and the paucity of available therapies. Despite the rarity and uncertainties of PCGDTL, a number of studies over the past decade were published about the pathologic, diagnostic, cytogenetic and clinical features of this disease. These diagnostic advances will open the doors to explore new therapeutics for this rare entity, specifically targeted and immune therapies. In this review, we highlight these advances, summarize the contemporary treatment approaches, and shed the light on future potential therapeutic targets.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 1-2","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40685101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina.","authors":"Carolina Mahuad,&nbsp;Otero Victoria,&nbsp;Korin Laura,&nbsp;Martinez Enriqueta,&nbsp;Warley Fernando,&nbsp;García Rivello Hernán,&nbsp;Cristaldo Nancy,&nbsp;Kohan Dana,&nbsp;Zerga Marta,&nbsp;Garate Gonzalo,&nbsp;Vicente Repáraz María de Los Ángeles,&nbsp;Aizpurua Florencia,&nbsp;Rojas Bilbao Erica,&nbsp;Cerana Susana,&nbsp;Funes Maria Eugenia,&nbsp;Plaza Iliana,&nbsp;Foncuberta Cecilia,&nbsp;Vijnovich Baron Anahí,&nbsp;Cranco Santiago,&nbsp;Vitriu Adriana,&nbsp;Gomez Mariela,&nbsp;Lavalle Justina,&nbsp;Casali Claudia,&nbsp;Clavijo Manuela,&nbsp;Melillo Luciana,&nbsp;Cabral Lorenzo Maria Cecilia,&nbsp;Miroli Augusto,&nbsp;Fischman Laura,&nbsp;Pavlove Maximiliano,&nbsp;Miodosky Marcela,&nbsp;Cugliari Silvana","doi":"10.1007/s44228-022-00008-4","DOIUrl":"https://doi.org/10.1007/s44228-022-00008-4","url":null,"abstract":"<p><p>There are no data in Argentina on the response rates to first-line treatment of classical Hodgkin Lymphoma (cHL) outside clinical trials. A total of 498 patients from 7 public and private hospitals in Argentina were retrospectively examined. The median follow-up was 37.4 months (CI 95% 17.7-63.5). The median time from diagnosis to treatment was 22 days (IQR 14-42), which was significantly longer in public hospitals (49.3 (IC 95% 38.5-60.2) versus 32.5 (IC 95% 27-38); <i>p</i> = 0.0027). A total of 96.8% of patients were treated with ABVD.:84.3% achieved complete remission (CR) and 6.02% partial remission (PR), being the CR rate higher in private hospitals. End-of-treatment metabolic CR was achieved in 85.4% (<i>n</i> = 373). The interim PET scan was widely used in our cohort (70.5%; <i>n</i> = 351), but in only 23.3% (<i>n</i> = 116) was the treatment strategy response-adapted. The 5-year progression-free survival (PFS) was 76% (CI 95% 70-81). The 2 and 5-years-OS rates were 91% (CI 95% 88-94%) and 85% (CI 95% 80-89%), respectively. No differences in OS were found between public and private institutions (<i>p</i> = 0.27). This is one of the largest retrospective cHL cohorts reported. In Argentina ABVD is the chemotherapy regimen of choice and, although it is well tolerated, it is not exempt from toxicity. We showed that early initiation of treatment impacts the induction results. Although the use of PET scan is widespread, only a minority of patients was treated with respons- adapted strategies. The use of PET-guided treatment is strongly encouraged.</p>","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":"4 1-2","pages":"44-51"},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40684668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}